CELLINK Q5 2020 Results and MatTek Acquisition
Continued strong organic growth, positive
result and strategic investments for the future
CELLINK
"LIFE SCIENCES
94
Q5: September - December 2020
Net sales amounted to SEK 239,216 thousand (SEK 50,189
thousand), which corresponds to an increase of 377% (118%)
compared to the corresponding period a year earlier, of which 73%
(47%) was organic growth.
EBITDA amounted to SEK 40,414 thousand (SEK -15,567
thousand), corresponding to a margin of 16.9% (-31.0%).
Profit for the period amounted to SEK 13,219 thousand
(SEK -18,895 thousand), which generates earnings per share after
dilution of SEK 0.26 (SEK -0.48). The result was positively affected by
the market valuation of the company's short-term investments of
SEK 5,122 thousand (SEK 272 thousand).
Rolling twelve-month net sales from consumables amounted to
SEK 35,091 thousand (SEK 15,699 thousand), an increase of 124%.
The share of total product sales was 11.9%, a decrease of 0.2
percentage points (12.1% in the comparison period).
September 2019 - December 2020
Net sales amounted to SEK 416,009 thousand (SEK 155,646
thousand), which corresponds to an increase of 167% (128%)
compared with the corresponding period a year earlier. Of the
increase, 48% (77%) was organic growth.
EBITDA amounted to SEK 816 thousand (SEK -12,216 thousand),
corresponding to a margin of 0.2% (-7.8%). Operating profit was
affected by costs for the listing on Nasdaq Stockholm and
acquisitions totaling SEK -18,264 thousand (SEK -6,395 thousand).
Profit for the period amounted to SEK -48,994 thousand
(SEK -18,314 thousand), which generates earnings per share after
dilution of SEK -1.10 (SEK -0.51). In addition to the listing and
acquisition costs, the net result was affected by the market valuation
of the company's short-term investments of SEK -1,211 thousand
(SEK 1,722 thousand).
Given the company's current growth phase, which is expected to
continue during 2021, the Board of Directors proposes no dividend
for the financial year 2019/2020.
CELLINK 2021, All rights reserved.View entire presentation